MedImmune
3
33M
3
0.09
2
- Areas of investment
Summary
In 1987 was created MedImmune, which is appeared as Corporate Investor. The venture was found in North America in United States. The main department of described Corporate Investor is located in the Maryland.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the MedImmune, startups are often financed by Sofinnova Partners, Apple Tree Partners. The meaningful sponsors for the fund in investment in the same round are Venrock Healthcare Partners, Venrock, Sofinnova Partners. In the next rounds fund is usually obtained by Auven Therapeutics, AstraZeneca, Redmile Group.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Corvidia Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Genetics, Medical.
The top activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year.
This organization was formed by Wayne Hockmeyer.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.09
- Investments by industry
- Therapeutics (2)
- Medical (2)
- Biotechnology (2)
- Education (1)
- Innovation Management (1) Show 4 more
- Investments by region
-
- United States (2)
- Switzerland (1)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Avg. valuation at time of investment
- 241M
- Group Appearance index
- 1.00
- Avg. company exit year
- 6
- Avg. multiplicator
- 8.35
- Strategy success index
- 0.67
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Corvidia | 25 Apr 2018 | Biotechnology, Health Care, Genetics, Medical, Therapeutics | Early Stage Venture | 60M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.